SI-BONE (SIBN) FY Conference June 10, 2025 11:20 AM ET Speaker0 Excellent. Well, thank you. Good morning, everyone. I think this is the last session that sits between people and lunch. So we'll jump right in here. I'm very pleased to welcome the management team from SI BONE Laura Francis, Chief Executive Officer and Anshul Maheshwari, Chief Financial Officer. Okay. Thank you. Very much appreciate you're making the trip here to Miami and look forward to kind of getting into the story here. I know Anshul and ...

SoFi (SOFI) 2025 Conference June 10, 2025 11:15 AM ET Speaker0 Okay. Good afternoon, everyone. Thank you for coming to our technology conference, the Museo Technology Conference. I have the pleasure of hosting Chris my friend Chris Lapointe today, CFO of SoFi. Thank you. Thank you having me, Dan. Of course. Give you a little background. Chris joined from Uber Technologies where he was global head of FP and A, corporate finance and fintech prior to Uber. Chris was VP of TNT Investment Banking at Goldman Sach ...

FIGS (FIGS) FY Conference June 10, 2025 11:15 AM ET Speaker0 Well, good morning. Thank you all for joining us. My name is Brian Nagel. I'm the senior equity research analyst here at Oppenheimer covering consumer growth and ecommerce. So this is our twenty fifth annual Oppenheimer consumer growth and ecommerce conference. We very much appreciate, you all attending. So I'm pleased to have with us our next presenting company, Figgs, and three of the company's senior executives. Katrina Spear, founder and CEO, ...

Turtle Beach (HEAR) FY Conference Summary Industry and Company Overview - The conference focused on Turtle Beach, a leading company in the gaming accessory industry, particularly known for its headsets and controllers [1][2] - The discussion highlighted the upcoming gaming cycle, including new hardware launches and significant game releases that are expected to impact accessory sales positively [3][4] Key Points and Arguments Upcoming Gaming Cycle - Anticipation for the Nintendo Switch 2 and its impact on accessory sales, with historical trends indicating strong initial sales for accessories following new console launches [4][5] - Excitement surrounding the release of GTA VI in May, which is expected to drive significant engagement and accessory purchases [6][14] Accessory Categories and Growth - Turtle Beach aims to differentiate its products by collaborating with console manufacturers to create complementary accessories that enhance the gaming experience [8][11] - The company is focusing on innovative audio features and new technologies across all platforms, including PC [10][12] Engagement-Driven Sales - High engagement games, such as GTA VI and Fortnite, are identified as key drivers for accessory purchases, with the expectation that increased playtime leads to higher accessory demand [13][15] - The company has successfully launched licensed products for popular games like Minecraft, indicating a strategy to tap into high-engagement titles [16][17] Market Dynamics and Replacement Cycles - Historically, the replacement cycle for gaming accessories has been around 2-3 years, driven by gamer engagement and technological advancements [21][22] - The pandemic created a surge in demand for gaming accessories, but a full replacement cycle has not yet been realized, presenting an opportunity for future growth as new hardware and games are released [23][25] Financial Performance and M&A Strategy - The acquisition of PDP has been transformative, broadening Turtle Beach's product portfolio and contributing to a more balanced revenue split between headsets and other categories [30][31] - The company has exceeded synergy expectations from the PDP acquisition, achieving over $13 million in synergies compared to the anticipated $10-12 million [32] - Future M&A activities will be informed by the success of the PDP acquisition, with a focus on accretive deals that enhance growth [34][35] Capital Allocation and Cash Flow - Turtle Beach anticipates $50 million in EBITDA for the year, with cash flow expected to be in the mid-$30 million range, supported by low capital requirements [37][38] - The company has a strong buyback program, having repurchased nearly $30 million in stock last year and approving an additional $75 million buyback program [36][39] Long-Term Strategy - The focus for the next 3-5 years includes consistent execution, adapting to market changes, and maintaining a leadership position in the gaming accessory space [47][50] - The company aims to balance investments in core business growth, M&A opportunities, and share buybacks to enhance shareholder value [49][51] Additional Important Insights - The company is preparing for a shift in revenue seasonality due to the upcoming releases, particularly GTA VI, which may create patterns similar to console launches [44][45] - The management emphasizes agility and quick adaptation to market changes, which has been a competitive advantage for Turtle Beach [48][49] This summary encapsulates the key insights from the Turtle Beach FY Conference, highlighting the company's strategic direction, market opportunities, and financial outlook.

Norfolk Southern (NSC) 2025 Conference June 10, 2025 11:15 AM ET Speaker0 All right, great. Going to go ahead and get started continuing on the rail track. At the conference this morning, we're very pleased to be joined by Norfolk Southern. From Norfolk, we have John Operating Officer and Jason Zanpey, Chief Financial Officer. Gentlemen, thanks very much for joining us. I think I saw Michael Barr and Luke are also in the audience, so thanks guys for joining and welcome to the conference. Speaker1 Thanks Chr ...

Cisco Systems (CSCO) Update / Briefing June 10, 2025 11:00 AM ET Speaker0 And a big hello to everyone around the world wherever you happen to be tuning in to this livestream. Welcome. Welcome to Cisco Live twenty twenty five from beautiful San Diego. We are streaming straight to you in any language that you need right here from the Cisco TV studio in the beautiful San Diego Convention Center. My name is Steve Moulter. I am one of your five broadcast hosts. So good to have you back here on the broadcast with ...

Summary of Barinthus Biotherapeutics plc (BRNS) Conference Call Company Overview - Barinthus Biotherapeutics plc focuses on next-generation immunotherapies targeting autoimmune and inflammatory diseases, utilizing a platform called SnapTI [4][5] Key Developments - The lead candidate, VTP 1000, is currently in phase one clinical trials for celiac disease, with expected data readout by the end of Q3 or early Q4 2025 [6][48] - The company has approximately $100 million in cash, providing a runway into 2027 with no debt or outstanding warrants [6][48] SnapTI Platform - SnapTI is a self-assembling nanoparticle platform designed to restore immune system balance by co-delivering multiple disease-associated antigens with an immunomodulator [5][11] - The platform allows for patient-friendly administration via intramuscular (IM) or subcutaneous (SubQ) routes, enhancing tolerability and broadening antigen coverage [12][13] Celiac Disease Focus - Celiac disease affects about 1% of the global population, with current treatment limited to a strict gluten-free diet [16] - VTP 1000 aims to rebalance the immune system by reducing T effector cells and stimulating T regulatory cells, addressing the underlying immune imbalance in celiac disease [18] Clinical Trials - The phase one trial is a double-blind, placebo-controlled study involving 18 patients in a single ascending dose (SAD) design, with safety and biomarker changes being key focuses [29][30] - A multiple ascending dose (MAD) portion has received FDA approval, involving 24 patients and a gluten challenge to assess efficacy [30] Viral-Based Platform - The company is winding down its viral-based platform, which includes VTP 300 for chronic hepatitis B and VTP 850 for prostate cancer, seeking partners to advance these programs [35][36] - Chronic hepatitis B presents a significant market opportunity, with over 250 million people affected globally and current treatments yielding low cure rates [37][38] Encouraging Data - VTP 300 is designed to stimulate both exhausted T cells and new T cells to combat hepatitis B, with a focus on achieving a functional cure defined as surface antigen loss after stopping nucleoside treatments [39][40] - Recent studies showed promising results, with 20-25% functional cure rates, significantly higher than current standard care [46][47] Financial Outlook - The company has no immediate plans for fundraising, relying on existing cash reserves and upcoming clinical data to guide future financial strategies [50]

McEwen Mining (MUX) Conference June 10, 2025 11:00 AM ET Speaker0 Good morning, all. We're so pleased to host Michael Ametting, the VP and general manager of McEwen Copper, who is the wonderful financier that brought Stellantis from Argentina into finance the Los Azules project. It wasn't some fancy investment banker. It was Michael's LinkedIn message. And Rob McEwen, the chairman and chief owner of McEwen Mining and McEwen Copper. Please bring us up to speed on all the good news. Speaker1 Thank you, John. ...

Summary of TEN Holdings (XHLD) Conference Call Company Overview - **Company Name**: TEN Holdings Incorporated - **Ticker Symbol**: XHLD - **Founded**: 2011, originally as Ten Events - **Location**: Langhorne, Pennsylvania - **Industry**: Event management and virtual broadcasting services - **Global Reach**: Collaborates with a Japanese company, vCube, which has a significant presence in the APAC region [6][9][12] Core Business Model - **Service Offering**: Provides technology-based solutions for various types of events, including in-person, virtual, and hybrid events [6][18][19] - **Target Market**: Fortune 500 and Fortune 1,000 companies [6][18] - **Event Types**: - **In-Person Events**: Traditional conferences and trade shows [18] - **Virtual Events**: Fully online events with live broadcasting capabilities [18] - **Hybrid Events**: Combination of in-person and virtual attendance [19] Financial Performance - **Recent IPO**: Successfully went public on Nasdaq approximately 90 days prior to the conference [5] - **Revenue**: The virtual company generated $3.5 million in revenue last year but incurred a loss of about $2 million [52] - **Gross Margins**: Virtual events have gross margins around 80-82%, while physical events vary based on equipment usage [50][51] Strategic Growth Plans - **Expansion Strategy**: Plans to grow both organically and inorganically, including potential mergers and acquisitions of complementary event-based companies [39][46] - **Technology Integration**: Incorporating AI capabilities to enhance event preparation and presentation quality [35][36] - **New Product Launch**: Introduction of a platform as a service product called TenPro, aimed at providing clients with technology to run their own events [37] Market Positioning - **Competitive Advantage**: Emphasizes high production quality and a full-service model that includes all aspects of event management [30][32] - **Client Base**: Works with various industries, with a notable presence in the pharmaceutical sector due to geographical proximity [28][29] Key Partnerships - **vCube**: The Japanese company that acquired Ten Events in 2021, holding a significant stake in TEN Holdings [9][12] - **Potential Collaborations**: Interest in exploring partnerships with other event-based companies, particularly those with established client bases and no debt [46][48] Additional Insights - **Market Resilience**: The company views its diverse service offerings as a hedge against market fluctuations, as it can adapt to changes in demand for physical, virtual, or hybrid events [33] - **Operational Costs**: Acknowledges the high costs associated with being a public company, which are expected to normalize as the company grows [53] Conclusion - **Future Outlook**: TEN Holdings is positioned for growth with a focus on enhancing its technology offerings and expanding its market presence through strategic partnerships and acquisitions [54][55]

Summary of Bio Techne Conference Call Company Overview - **Company**: Bio Techne - **Analyst**: Matt Sykes, Goldman Sachs - **CFO**: Jim Hipple - **Head of IR**: David Claire Key Highlights from Fiscal Q3 Results - **Overall Growth**: Achieved 6% organic growth in Q3 despite macroeconomic headwinds [5][6] - **Protein Sciences Segment**: Notable 7% growth, driven by widespread demand across core reagents and instrument platforms [5][6] - **Large Pharma Market**: Contributed significantly to growth, accounting for 30% of total revenue, with double-digit growth observed [6][7] U.S. Academic Market Insights - **Revenue Contribution**: U.S. academic customers represent approximately 12% of total revenue [12] - **Market Volatility**: Academic market has been volatile due to budget cuts and NIH funding fluctuations, but core reagents remain stable [10][11] - **International Exposure**: Academic markets outside the U.S., particularly in Europe, have shown robust growth, helping to stabilize overall academic revenue [14] Tariff Exposure and Mitigation - **Manufacturing Resilience**: Most products manufactured in the U.S., with core reagents exempt from tariffs, minimizing exposure [16][17] - **Mitigation Strategies**: Ability to ramp up production in non-China facilities to avoid tariff impacts [18] China Market Performance - **Revenue Impact**: China accounts for about 8% of total revenue, with recent quarters showing negative mid-single-digit growth [20][21] - **Customer Sentiment**: A slight shift towards optimism among customers in China, indicating potential for future growth [22][23] Biopharma Market Dynamics - **Market Segmentation**: Distinction between large pharma and biotech, with large pharma showing more stability and less volatility [26][27] - **R&D Budgets**: Anticipated increases in R&D budgets for large pharma in 2025, despite recent caution due to external factors [28][30] Instrumentation and Consumables - **Growth in Instrumentation**: Achieved upper single-digit growth in instrumentation, driven by strong consumable pull-through [43][44] - **Competitive Advantage**: Unique product offerings with minimal direct competition in key instrument platforms [45][46] GMP Reagents and Cell & Gene Therapy - **Revenue Dynamics**: Growth in GMP reagents is lumpy due to reliance on clinical trial purchases, but reflects progress in customer development [50][52] - **Wilson Wolf Acquisition**: Bio Techne owns 20% of Wilson Wolf, with plans to acquire the remaining 80% based on performance metrics, enhancing growth potential in cell therapy [62][65] Spatial Biology and Diagnostics - **Market Position**: Bio Techne is a leading player in spatial biology, with a focus on translational applications and a profitable business model [67][68] - **COMET Platform**: New automated solution for spatial biology, capable of multi-omic detection, enhancing reagent pull-through [69][70] Financial Outlook - **Q4 Expectations**: Anticipating low single-digit growth due to continued market challenges, particularly in large pharma [73][75] - **Margin Projections**: Expected decline in operating margins due to tariff impacts, but viewed as a temporary issue [76][77] Capital Allocation Strategy - **Share Repurchase Plan**: Announced a $500 million share repurchase plan, indicating confidence in company valuation and a tactical approach to capital allocation [78][81] - **M&A Strategy**: Continued focus on M&A as a key growth strategy, particularly targeting private companies [80][82]